Medindia
Medindia LOGIN REGISTER
Advertisement

FDA Says, 'Wait' To Dying Men; Coast-To-Coast Prostate Cancer Demonstrations on May 30th in Protest of FDA Failure to Approve Safe, Effective Immunotherapy

Tuesday, May 13, 2008 General News
Advertisement
DUBLIN, Ohio, May 12 On May 30, 2008, CareToLive will taketo the streets with coast-to-coast protests in Chicago, New York,Philadelphia, Cleveland, Madison, Atlanta, Seattle, Dearborn, and Tampa.Joining us will be the Cancer Cure Coalition, the Abigail Alliance, A Right ToLive, and the Sarcoma Foundation of America. We are asking all patientadvocates to come out and attend a protest.
Advertisement

1 in 6 men get prostate cancer. 75 American men die from it every day. TheFDA has not approved a treatment for stage IV prostate cancer in over 43years.
Advertisement

CareToLive, a not for profit corporation, seeks transparency andaccountability from the FDA, as to why they disregarded the advice of theirhand selected Congressionally mandated Advisory Panel of experts, who votedProvenge overwhelmingly safe and effective. Without cause or explanation, inan unprecedented action, the FDA denied licensure. We are seeking immediateaccess to Provenge for all men with end stage prostate cancer.

Over a year has passed, and 27,000 American men have died without hope,since the FDA denied the licensure of Provenge, an immunotherapy the FDA panelvoted 17-0 safe and overwhelmingly voted effective. This is a noninvasive,non-toxic, immune building treatment, which works by employing your own body'shealthy cells to fight the cancer.

Men like Eduardo Garcia, who have had the 3 treatments, have gone frombeing incapacitated, to living healthy, productive lives, for as long as sevenyears and counting. Dendreon, the company that perfected this treatment, alsohas similar treatments for breast, ovarian, colon, lung, kidney, and cervicalcancers, in their sights.

The dysfunctional FDA's reason for delay has never been explained, as itwas not science based, since survival and safety have been clearlydemonstrated.

CareToLive filed a Citizens Petition for the FDA to reconsider thewrongful denial, (the only recourse the FDA allows), on July 26, 2007. The FDAhas failed to follow Federal regulation and to this day they have not properlyresponded to our Petition, which seeks immediate access to Provenge for thesedesperate men. The FDA also refuses to respond to the CareToLive Freedom ofInformation Act request, which they know would prove that a few FDA insiders,who cared more about serving their own interests, rather than the bestinterest of the patients, purposely sabotaged Provenge.

"In memory of our members who have recently passed away, never having beengiven the chance Provenge recipient Eduardo Garcia had, we will continue tofight on, every day, in every way we can. Please come out and join us,"CareToLive spokesperson, Mike Kearney, said.LOCATIONS: Seattle, Washington -- 1 PM PDT Westlake Park (Downtown) - 400 Pine St Coordinator - Jason Burdine [email protected] Co-Coordinator - Monica Sagen - [email protected] Chicago, Illinois -- 3 PM CDT ASCO / McCormick Place - 2301 S. Lake Shore Drive Coordinator - Sean Morgan - [email protected] Co-coordinator - Arnie Mass - [email protected] Cleveland, Ohio -- 4 PM EDT Public Square outside terminal tower - downtown Coordinator - Kerry Donahue - [email protected] Co-coordinator - Mike Bauman - [email protected] Dearborn, Michigan -- 3 PM EDT Rep. John Dingell's Office - 19855 West Outer Drive Coordinator - Gregg Burch - [email protected] Madison, Wisconsin -- 4 PM CDT Wisconsin State Capitol Building - 2 East Main Street Coordinator - Melody Davis - [email protected] Tampa, Florida -- 3 PM EDT H. Lee Moffitt Cancer Center & Research Institute University of South Florida 12902 Magnolia Drive Coordinator - Terry Rush - [email protected] Philadelphia, Pennsylvania -- 2 PM EDT 2 PM Assemble and pass out flyers at 12th & Market Street for march to FDA at 4 PM - 200 Chestnut Street U.S.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close